Achieving 95% Cross-Methodological Concordance in HER2 Testing

Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes

(2010) Cathy B Moelans et al.   MODERN PATHOLOGY

Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis

(2009) Caterina Marchiò et al.   JOURNAL OF PATHOLOGY

Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event

(2009) I-Tien Yeh et al.   MODERN PATHOLOGY

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine

(2009) J. S. Ross et al.   ONCOLOGIST

Using a Higher Cutoff for the Percentage of HER2+ Cells Decreases Interobserver Variability in the Interpretation of HER2 Immunohistochemical Analysis

(2008) Omar Hameed et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system

(2008) Allen M Gown et al.   MODERN PATHOLOGY